Novartis AG (NVSEF)
150.12
+0.31
(+0.21%)
USD |
OTCM |
Oct 26, 16:00
Novartis Enterprise Value : 316.53B for Oct. 26, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 26, 2026 | 316.53B |
| October 23, 2026 | 315.95B |
| October 22, 2026 | 309.32B |
| October 21, 2026 | 309.32B |
| October 20, 2026 | 309.82B |
| October 19, 2026 | 309.82B |
| October 16, 2026 | 305.14B |
| October 15, 2026 | 305.91B |
| October 14, 2026 | 293.98B |
| October 13, 2026 | 293.98B |
| October 12, 2026 | 303.83B |
| October 09, 2026 | 297.97B |
| October 08, 2026 | 290.22B |
| October 07, 2026 | 287.42B |
| October 06, 2026 | 287.42B |
| October 05, 2026 | 287.99B |
| October 02, 2026 | 287.39B |
| October 01, 2026 | 299.71B |
| September 30, 2026 | 299.71B |
| September 29, 2026 | 307.04B |
| September 28, 2026 | 308.99B |
| September 25, 2026 | 299.76B |
| September 24, 2026 | 302.59B |
| September 23, 2026 | 295.04B |
| September 22, 2026 | 295.04B |
| Date | Value |
|---|---|
| September 21, 2026 | 294.80B |
| September 18, 2026 | 286.47B |
| September 17, 2026 | 301.78B |
| September 16, 2026 | 301.78B |
| September 15, 2026 | 301.78B |
| September 14, 2026 | 288.39B |
| September 11, 2026 | 293.91B |
| September 10, 2026 | 294.25B |
| September 09, 2026 | 295.26B |
| September 08, 2026 | 342.40B |
| September 04, 2026 | 342.40B |
| September 03, 2026 | 342.40B |
| September 02, 2026 | 328.75B |
| September 01, 2026 | 338.45B |
| August 31, 2026 | 307.18B |
| August 28, 2026 | 341.21B |
| August 27, 2026 | 341.21B |
| August 26, 2026 | 341.21B |
| August 25, 2026 | 341.21B |
| August 24, 2026 | 341.21B |
| August 21, 2026 | 330.24B |
| August 20, 2026 | 330.24B |
| August 19, 2026 | 334.62B |
| August 18, 2026 | 315.82B |
| August 17, 2026 | 308.87B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Roche Holding AG | -- |
| Addex Therapeutics Ltd. | 2.224M |
| Oculis Holding AG | 211.49M |
| Sandoz Group AG | -- |
| Galderma Group AG | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.257B |
| Revenue (Quarterly) | 14.41B |
| Total Expenses (Quarterly) | 11.14B |
| EPS Diluted (Quarterly) | 1.705 |
| Gross Profit Margin (Quarterly) | 74.47% |
| Profit Margin (Quarterly) | 22.61% |
| Earnings Yield | 4.41% |
| Operating Earnings Yield | 5.61% |
| Normalized Earnings Yield | 4.738 |